ClinicalTrials.gg
CompletedNCT04825951Updated Feb 3, 2023

Dentofacial Effects Of Two Non-Compliance Appliances In The Treatment Of Growing Skeletal Class III Patients

An interventional study of CS 2000 in Malocclusion, Angle Class III, sponsored by Alexandria University. Completed at 1 site in Egypt. Open to participants aged 8 Years to 11 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-02-03.

Sponsored by Alexandria University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
33
Allocation
Randomized
Ages
8 Years to 11 Years
Sex
All
01

Study summary

Early orthodontic treatment of Class III malocclusions with skeletal and dentoalveolar imbalances, represents a continuous dilemma. This difficulty starts from their meticulous diagnosis and treatment planning till reaching satisfactory results and finally stability. Some appliances could be used to correct growing skeletal Class III patients, improving the skeletal and dentoalveolar relationships, creating proper conditions for final orthodontic treatment, more importantly avoiding surgery. These appliances remove patient compliance from the equation.

Read the detailed description

Aim of the work: Evaluate the skeletal, dentoalveolar and soft tissue effects of two different force application systems which are the pulling force (CS 2000® appliance/ CS appliance) and the pushing force (Reversed Forsus fatigue-resistant device/ RF appliance).

Materials and methods: A randomized controlled clinical trial will be conducted to address the aim of the study. Thirty three growing skeletal Class III patients (9-11 years) will be recruited upon a lateral cephalometric x-ray. Subjects complying with the inclusion criteria will be randomly assigned using a computer-generated list to one of the three groups Group I: Eleven patients treated with CS2000 appliance, Group II: Eleven patients treated with reversed Forsus Fatigue Resistant device and Group III: control group of Eleven untreated patients with a ratio of 1:1:1 allocation. A CBCT will be made before installing the appliances. After gaining a 2 mm positive overjet or a 6 months period, alginate impressions will be poured and dental casts will be made. Photographs and CBCTs will also be performed to record the dentofacial effect of the used appliances.

Keywords: Cone beam computed tomography, growing skeletal Class III, CS 2000® appliance, Reversed Forsus Fatigue resistant device.

02

Conditions studied

  • Malocclusion, Angle Class III

Keywords

  • Cone beam computed tomography
  • growing skeletal Class III
  • CS 2000® appliance
  • Reversed Forsus Fatigue resistant device
03

In context

Malocclusion, Angle Class III

57 studies on the registry are indexed under Malocclusion, Angle Class III; 11 are open to participants now.

This study's enrollment of 33 is close to the median of 32 across 53 interventional studies indexed under Malocclusion, Angle Class III.

Browse Malocclusion, Angle Class III studies →

Lead sponsor

Alexandria University is the lead sponsor of 604 studies on the registry; 140 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
8 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age range from 8 years to 11 years.
  • Cervical vertebrae maturation index (CVMI 2 and 3) identified on the lateral cephalometric radiograph.
  • Angle Class III molar relation.
  • Skeletal class III ANB ranges between (-4) - (0).
  • Wits appraisal ranges between (0) - (-5).
  • Patients with good oral hygiene, and a healthy periodontal condition.
  • Reversed over jet (-1) - (-6).
  • Normal vertical growth pattern (SN/MP angle 28˚-38˚).

Exclusion criteria

Exclusion Criteria:

  • A discrepancy between centric relation and maximum intercuspation.
  • Patients who underwent previous orthodontic treatment.
  • Patients currently receiving drug therapy that may affect orthodontic tooth movement.
  • Congenitally missing teeth or extracted teeth.
  • History of systemic disease or craniofacial syndromes or presence of cleft.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
33 participants (actual)

Study arms

  • Active comparator
    CS 2000 appliance

    treating growing skeletal Class III patients

    Other: CS 2000

  • Active comparator
    Reversed Forsus Fatigue resistant appliance

    treating growing skeletal Class III patients

    Other: CS 2000

  • No intervention
    Control

    A group of untreated skeletally growing class III patients will be recruited to account for the possible effects of growth in the treatment groups. This group matches the treated groups in malocclusion, stages of skeletal maturation, and mean observation period. Those patients will be treated after the period of the study.

Interventions

  • OtherCS 2000

    treating growing Skeletal growing Class III patients

    Also known as: Reversed Forsus Fatigue resistant appliance

06

What researchers measure

Primary outcomes

  1. Skeletal readings angles

    SNA in degrees SNB in degrees ANB in degrees SN-MP in degrees

    Time frame: 6 months

  2. Skeletal readings percetanges

    LAFH in percentage

    Time frame: 6 months

  3. Skeletal readings in millimeters

    Wits appraisal in millimeters

    Time frame: 6 months

  4. Dental readings angles

    U1-PP in degrees U1- NA in degrees L1-MP in degrees L1-NB in degrees

    Time frame: 6 months

  5. Dental readings in millimeters

    U1-NA millimeters L1-NB in millimeters.

    Time frame: 6 months

  6. Soft tissue readings in millimeters

    UL- E plane in millimeters LL- E plane in millimeters

    Time frame: 6 months

Secondary outcomes

  1. Changes in airway

    difference in airway volume in cubic millimeters .

    Time frame: 6 months

  2. Changes in TMJ

    anterior, posterior, superior and medial joint space in cubic milimeters.

    Time frame: 6 months

07

Study locations

1 site
  • Alexandria University Faculty of Dentistry
    Alexandria, 03, Egypt
08

References and documents

Publications

  • Oliveira PM, Cheib-Vilefort PL, de Parsia Gontijo H, Melgaco CA, Franchi L, McNamara JA Jr, Souki BQ. Three-dimensional changes of the upper airway in patients with Class II malocclusion treated with the Herbst appliance: A cone-beam computed tomography study. Am J Orthod Dentofacial Orthop. 2020 Feb;157(2):205-211. doi: 10.1016/j.ajodo.2019.03.021. PubMed 32005472 ↗
  • World Medical Association.. World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. Bull World Health Organ. 2001;79(4):373-4. Epub 2003 Jul 2. No abstract available. PubMed 11357217 ↗

Individual participant data

Plan to share: No — TREATMENT OF GROWING SKELETAL CLASS III PATIENTS

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2021 to primary completion in Dec 2021, 7 months.

Of 37 non-industry interventional studies with no phase under Malocclusion, Angle Class III, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 7 months is below that.

Counting every sponsor, half of 38 studies reached it within 13 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2021
First posted
Apr 1, 2021
StartActual
May 1, 2021
Primary completionActual
Dec 30, 2021
CompletionActual
Dec 30, 2021
Last update
Feb 3, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 3, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04825951
Responsible party
Bassant Alaa (principal investigator, Alexandria University) — Principal investigator
First posted
Apr 1, 2021
Start date
May 1, 2021
Primary completion
Dec 30, 2021
Completion
Dec 30, 2021
Last update
Feb 3, 2023

Study contacts

Bassant A Abbas, PHD resident
principal investigator · Alexandria University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion